A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-Deficient Blood Donors
Phase of Trial: Phase III
Latest Information Update: 08 Mar 2016
At a glance
- Drugs Iron isomaltoside 1000 (Primary)
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Pharmacosmos
- 01 Mar 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 01 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 18 Aug 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Oct 2015 to 1 Sep 2016.